Skip to main content

No Benefit of Corticosteroids in Neonatal Heart Surgery

NEW YORK (Reuters Health) Jan 25 - Methylprednisolone does not improve outcomes in newborns undergoing cardiac surgery, and it may increase the risk of infection in some of those infants, an observational analysis suggests.
"These data reinforce the need for a large randomized trial in this population," the authors conclude in their report, published online January 23 in Pediatrics.
Dr. Sara K. Pasquali, with Duke University Medical Center in Durham, North Carolina, and colleagues explain that corticosteroids are used in pediatric heart surgery to reduce the inflammatory response triggered by cardiopulmonary bypass. But while inflammatory markers are reduced, the clinical benefits are being increasingly questioned.
Using a congenital heart surgery database and another that provided data on medication usage, the researchers identified 3,180 newborns who had heart surgery over a five-year period. Twelve percent received methylprednisolone on the day before surgery, 28% received it on the day of surgery, 22% received it on both days, and 38% received no perioperative steroids at all.
Neither of the two primary outcomes -- in-hospital mortality and postoperative length of stay (LOS) - differed significantly between babies who did and did not receive steroids, according to the report.
Specifically, unadjusted in-hospital mortality was 10.5% with no steroids, compared to 13.7% with methylprednisolone on the day of surgery, 11.1% with methylprednisolone on the day before surgery, and 10.9% with treatment on both days (p=0.13)
Adjusted mortality odds ratios in the three groups given methylprednisolone were 1.28, 0.95, and 1.00, respectively.
LOS was 14 days in all groups except the one given methylprednisolone on the day of surgery, for which the LOS was 15 days, the report indicates.
Overall, the risk of postoperative infection was similar in all groups. However, when patients were classified as high or low surgical risk, there was a significantly increased likelihood of infection across all methylprednisolone regimens in the low-surgical-risk group, Dr. Pasquali and colleagues report.
"This multicenter observational analysis of methylprednisolone in neonates undergoing heart surgery, along with other recent studies, calls into question the benefits of corticosteroids in children undergoing heart surgery," they conclude, "and furthermore supports the need for an adequately powered clinical trial in this population."

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more